Semaglutide vs Tirzepatide vs Retatrutide: Complete 2026 Comparison

Semaglutide vs tirzepatide vs retatrutide compared: weight loss results, mechanisms, side effects, cost, and which GLP-1 is right for you. Updated with Phase 3 data.

Regimen Team · Updated · Published · 12 min read

The Bottom Line

Semaglutide (commonly called “sema”), tirzepatide (“tirz”), and retatrutide (“reta”) represent three generations of GLP-1 weight loss medications - single, dual, and triple receptor agonists respectively. Semaglutide (Ozempic/Wegovy) targets GLP-1 only and produces ~15% weight loss. Tirzepatide (Mounjaro/Zepbound) targets GLP-1 + GIP and produces ~20.9% mean weight loss (up to 22.5% in people who stayed on treatment). Retatrutide targets GLP-1 + GIP + glucagon and produces ~25.0% mean weight loss at 80 weeks (up to 28.3% in people who stayed on treatment) - the highest of any obesity medication ever studied. Semaglutide and tirzepatide are FDA-approved. Retatrutide is in Phase 3 trials, with an FDA filing planned for early 2027. This guide compares all three across every dimension that matters: weight loss, mechanism, side effects, cost, availability, and who each one is best for. Calculate doses for all three compounds with our free GLP-1 dose calculator.

Regimen is a GLP-1 tracker app that logs your GLP-1 and shows your estimated level between shots.

This guide is for informational purposes only. Retatrutide is an investigational compound not yet FDA-approved. Semaglutide and tirzepatide require prescriptions. Work with a licensed healthcare provider for any medication decisions.

In this guide:

On Ozempic? Regimen’s Ozempic app logs the shot in one tap, reminds you before the next one, and ties your side effects and weight to each dose step.

Wondering what is normal? Ozempic side effects by dose has every rate from Novo’s label, including the three warnings most articles skip.

The Quick Answer: Which One Loses the Most Weight?

Retatrutide. In Phase 3 trials, participants on 12mg retatrutide lost an average of 25.0% of their body weight over 80 weeks, up to 28.3% (70.3 lbs / 31.9 kg) in people who stayed on treatment (TRIUMPH-1). Tirzepatide at 15mg produced ~20.9% mean weight loss (up to 22.5% in people who stayed on treatment) over 72 weeks in SURMOUNT-1. Semaglutide at 2.4mg produced approximately 15% weight loss over 68 weeks.

But weight loss isn’t the only factor. Semaglutide has the most real-world safety data and is the most accessible. Tirzepatide has the best balance of efficacy and availability. Retatrutide has the highest efficacy but isn’t FDA-approved. Each has a different risk-benefit profile depending on your situation.

Which Is Better, Semaglutide or Tirzepatide?

Tirzepatide, if the goal is weight loss. In SURMOUNT-5, a 72-week trial that put the two side by side in adults with obesity, people on tirzepatide lost 20.2% of their body weight on average, against 13.7% on semaglutide. Both come as approved weekly shots with mostly stomach side effects, and semaglutide has the longer track record.

Semaglutide (Ozempic, Wegovy)Tirzepatide (Mounjaro, Zepbound)
Weight loss at 72 weeks (SURMOUNT-5)13.7%20.2%
Weekly dose in the trial1.7 or 2.4 mg10 or 15 mg
Acts onGLP-1GLP-1 and GIP

Master Comparison Table

FactorSemaglutide (Ozempic/Wegovy)Tirzepatide (Mounjaro/Zepbound)Retatrutide (LY3437943)
DeveloperNovo NordiskEli LillyEli Lilly
Receptor targetsGLP-1 onlyGLP-1 + GIP (dual)GLP-1 + GIP + Glucagon (triple)
Generation1st gen GLP-1 RA2nd gen (dual agonist)3rd gen (triple agonist)
Max studied dose2.4 mg/week15 mg/week12 mg/week
Average weight loss~15% body weight~20.9% mean (up to 22.5% in people who stayed on treatment)~25.0% mean (up to 28.3% in people who stayed on treatment)
Average lbs lost~34 lbs~48 lbs (up to ~52 in people who stayed on treatment)~62 lbs (up to ~70 in people who stayed on treatment)
Key trialSTEP 1SURMOUNT-1TRIUMPH-1
FDA statusApproved (2021)Approved (2022)Phase 3 (FDA filing planned Q1 2027)
Brand namesOzempic, Wegovy, RybelsusMounjaro, ZepboundNone yet
Half-life~7 days~5 days~6 days
Injection frequencyOnce weeklyOnce weeklyOnce weekly
Insurance coveragePossiblePossibleNo
Unique advantageMost safety data, longest track recordBest efficacy/tolerability balanceHighest weight loss, energy expenditure

How Each One Works (Mechanism of Action)

ReceptorWhat It DoesSemaTirzReta
GLP-1Reduces appetite, slows stomach emptying, improves insulinYesYesYes
GIPEnhances fat metabolism, synergizes with GLP-1NoYesYes
GlucagonIncreases energy expenditure, burns liver fat, raises metabolic rateNoNoYes

All three are peptides, lab-made versions of gut hormones; is Ozempic a peptide explains what that means and which drugs count.

Think of it as a volume dial:

  • Semaglutide turns down your hunger (1 lever)
  • Tirzepatide turns down hunger AND improves fat processing (2 levers)
  • Retatrutide turns down hunger, improves fat processing, AND turns up your body’s calorie burn (3 levers)

Each additional receptor doesn’t just add to the effect - it compounds it. The glucagon receptor in retatrutide is particularly significant because it’s the first weight loss compound that actively increases energy expenditure rather than just reducing energy intake.

Pro Tip

The glucagon receptor is why reta users report feeling “warmer” - their metabolism is literally running hotter. This also explains why retatrutide may preserve lean muscle mass better than the other two during weight loss: when the body is burning more fat for energy through glucagon activation, it’s less likely to break down muscle tissue.

Weight Loss Results: The Data

Semaglutide (STEP 1 Trial)

  • Dose: 2.4mg/week
  • Duration: 68 weeks
  • Average weight loss: 14.9% body weight
  • Patients reaching 10%+ loss: ~70%
  • Patients reaching 20%+ loss: ~32%

Tirzepatide (SURMOUNT-1 Trial)

  • Dose: 15mg/week
  • Duration: 72 weeks
  • Average weight loss: ~20.9% body weight (treatment-regimen estimand); up to 22.5% in people who stayed on treatment (efficacy estimand)
  • Patients reaching 5%+ loss: 91% (treatment-regimen estimand)
  • Patients reaching 20%+ loss: 57% (treatment-regimen estimand)

Retatrutide (TRIUMPH-1 Trial)

  • Dose: 12mg/week
  • Duration: 80 weeks
  • Average weight loss: ~25.0% body weight (treatment-regimen estimand, the figure in NEJM); up to 28.3% or 70.3 lbs (31.9 kg) in people who stayed on treatment (efficacy estimand)
  • Patients reaching 25%+ loss: 62.5% (efficacy estimand)
  • Patients reaching 30%+ loss: 45.3% (efficacy estimand)

Additional retatrutide findings from TRIUMPH-1:

  • Also produced significant improvements in knee osteoarthritis pain
  • Reduced cardiovascular risk markers (non-HDL cholesterol, systolic blood pressure)
  • 9mg group achieved 23.7% weight loss (25.9% in people who stayed on treatment) - nearly as effective as 12mg with fewer side effects

Community Insight

In community discussions, the practical comparison often comes down to: “sema got me 30 lbs, tirz got me another 20, and reta is where people go when they’ve plateaued on tirz.” The triple agonist seems to break through plateaus that the dual agonist can’t, likely because the glucagon component introduces a completely new metabolic pathway. This upgrade path (sema to tirz to reta) is becoming the standard progression in the peptide community.

Side Effects Compared

Side EffectSemaglutideTirzepatideRetatrutide
NauseaCommonCommonCommon (more intense at 8mg+)
Decreased appetiteVery commonVery commonVery common (strongest of the three)
DiarrheaCommonCommonCommon
ConstipationCommonCommonCommon
Injection site reactionsOccasionalOccasionalMore frequent
VomitingOccasionalOccasionalOccasional (more common at higher doses)
Heart rate increaseSmall increase (on label)Small increase (on label)Dose-dependent increase (Phase 2)
FatigueOccasionalOccasionalOccasional
Body heat / thermogenesisNot reportedNot reportedCommon at 6mg+ (unique to reta)

Key differences:

  • Semaglutide has the mildest side effect profile overall but also the least weight loss
  • Tirzepatide has a similar side effect profile to semaglutide with modestly higher efficacy
  • Retatrutide has the most intense side effects - particularly the glucagon-driven nausea at higher doses and the heart rate elevation - but also the most weight loss

For detailed side effect management at each retatrutide dose tier, see our Retatrutide Side Effects Guide.

Cost and Availability

FactorSemaglutideTirzepatideRetatrutide
List price$1,028-1,349/month$1,087/month (Zepbound)Not available
Manufacturer self-pay$199-499/month (NovoCare)$299-699/month (LillyDirect)Not available
With insuranceAs little as $25/month (savings card)As little as $25/month (savings card)Not covered
Regulated accessWidely availableWidely availableClinical trials only
Prescription requiredYes (FDA-approved)Yes (FDA-approved)N/A (not approved)

US dollars, manufacturer pages, last checked October 2026. Detail by dose: how to get a GLP-1 in the US.

The practical reality for most people:

  • If you have insurance that covers GLP-1s, tirzepatide (Zepbound) is the best value - better results than semaglutide at similar out-of-pocket cost
  • Retatrutide has no legitimate price or regulated supply yet, because it isn’t approved anywhere

Warning

Retatrutide is not approved anywhere, and outside a clinical trial there is no regulated supply. In August 2026 the FDA sent a warning letter treating a product sold as “GLP-3 Reta” as an unapproved new drug. If you use retatrutide anyway, work with a healthcare provider who can monitor your progress.

The Upgrade Path: Sema to Tirz to Reta

A growing number of people follow a progression through all three compounds. Here’s how it typically works:

Stage 1: Semaglutide (months 1-6+)

  • Start here if you’re new to GLP-1 medications
  • Most accessible, most safety data, insurance-friendly
  • Expect 10-15% body weight loss
  • Move to Stage 2 if: weight loss stalls after 3+ months at max dose, or you want faster results

Stage 2: Tirzepatide (months 6-12+)

  • Upgrade when semaglutide plateau hits
  • Dual mechanism often restarts weight loss
  • Expect additional 7-10% body weight loss
  • Move to Stage 3 if: plateau on max tirz dose after 2+ months AND you’ve optimized diet/exercise

Stage 3: Retatrutide (investigational)

  • The “final level” for maximum weight loss
  • Triple mechanism breaks through dual-agonist plateaus
  • Expect additional 5-10% body weight loss beyond tirzepatide
  • Not everyone needs this stage - many people reach their goal weight on tirzepatide

Make sure you’ve optimized diet, training, and sleep before stepping up to retatrutide, and confirm you’re working with a provider who can monitor the transition.

Community Insight

Not everyone follows this path linearly. Some people start directly on tirzepatide (especially with insurance coverage for Zepbound). Others jump from sema to reta, skipping tirz entirely. The “right” path depends on your starting point, insurance situation, risk tolerance, and weight loss goals. There’s no wrong order - there’s only what works for your situation.

Which One Is Right for You?

Start with semaglutide if:

  • You’re new to GLP-1 medications and want the safest entry point
  • Your insurance covers Ozempic or Wegovy
  • You have 30-50 lbs to lose
  • You prefer the compound with the most published long-term safety data

Choose tirzepatide if:

  • You’ve plateaued on semaglutide or want stronger initial results
  • Your insurance covers Mounjaro or Zepbound
  • You have 50-80+ lbs to lose
  • You want the best balance of efficacy, safety, and accessibility

Consider retatrutide if:

  • You’ve genuinely plateaued on tirzepatide at max dose
  • You have a BMI of 40+ and need maximum weight loss
  • You’re comfortable with an investigational compound
  • You train regularly and prioritize muscle preservation during fat loss
  • You’re working with a provider who can monitor your labs and progress

Tracking Any GLP-1 Protocol

Whether you’re on your first week of semaglutide or switching from tirzepatide to retatrutide, tracking makes every protocol more effective. The Regimen app supports all three compounds with dose logging, medication level modeling, weight trends, side effect logging, and progress photos.

Semaglutide Tracker · Tirzepatide Tracker · Retatrutide Tracker · GLP-1 Dose Calculator · Tirzepatide Reconstitution Calculator

Frequently Asked Questions

Which GLP-1 medication causes the most weight loss?

Retatrutide produces the most weight loss in clinical trials - about 25.0% average body weight at 12mg over 80 weeks, up to 28.3% in people who stayed on treatment (Phase 3 TRIUMPH-1). Tirzepatide is second at ~20.9% mean, up to 22.5% in people who stayed on treatment (SURMOUNT-1). Semaglutide is third at approximately 15% (STEP 1). However, retatrutide is not yet FDA-approved, so tirzepatide is currently the most effective approved option.

Can I switch from semaglutide to tirzepatide?

Yes, this is a common transition. Most providers recommend finishing your current semaglutide dose, waiting one week (a gap week), then starting tirzepatide at 2.5mg and titrating up. The GLP-1 receptor effects will feel familiar, and many people tolerate the switch well.

Can I switch from tirzepatide to retatrutide?

Yes, but start retatrutide at 2mg regardless of your tirzepatide dose. The glucagon receptor is new to your body and requires its own tolerance-building period. Allow a 1-week gap between your last tirzepatide dose and first retatrutide dose.

Is retatrutide safe?

Retatrutide has shown acceptable safety in Phase 2 and Phase 3 clinical trials, with side effects similar to (but somewhat more intense than) tirzepatide. However, it does not have FDA approval and lacks the years of real-world safety data that semaglutide and tirzepatide have.

When will retatrutide be FDA approved?

TRIUMPH-1, the main obesity trial, reported in May 2026, and TRIUMPH-2 and TRIUMPH-3 in July. Lilly has said it will file for FDA approval in the first quarter of 2027, so a decision would come after that.

What is the best GLP-1 for someone just starting?

For most people starting their first GLP-1 medication, semaglutide or tirzepatide are the recommended options since both are FDA-approved with established safety profiles. Tirzepatide generally produces more weight loss than semaglutide (~20.9% vs ~15%), but semaglutide has a longer track record.

Do I need all three, or can I just start with retatrutide?

You don’t need to progress through all three compounds. Some people start on tirzepatide and never need anything else. Others reach their goal on semaglutide alone. The upgrade path exists for people who plateau and need a stronger mechanism, but it’s not a required sequence.

Is Zepbound the same as Mounjaro?

Yes, it’s the same drug. Both are tirzepatide from Lilly, at the same weekly doses of 2.5 to 15 mg. The difference is the approval: Zepbound is for weight management and Mounjaro is for type 2 diabetes, which affects how insurance covers each one.

Is Zepbound the same as Ozempic?

No. Zepbound is tirzepatide, which acts on two receptors, GIP and GLP-1. Ozempic is semaglutide, which acts on GLP-1 only. In SURMOUNT-5, a head-to-head trial of the two, people on tirzepatide lost 20.2% of their weight at 72 weeks, against 13.7% on semaglutide.

What is the difference between semaglutide and tirzepatide?

Semaglutide (Ozempic, Wegovy) acts on one receptor, GLP-1. Tirzepatide (Mounjaro, Zepbound) acts on two, GIP and GLP-1. Tirzepatide’s half-life is about 5 days and semaglutide’s about 7. Both mostly cause stomach side effects like nausea, diarrhea and constipation.

Get the app

Track your GLP-1 protocol in Regimen.

Reminders that keep you on track, and built-in pattern detection that shows how your body responds.

Free to download. Free for your first compound.

Regimen app Today view with doses and estimated levels

Keep reading · GLP-1

Best GLP-1 Tracker App in 2026: Free & Paid Apps for Ozempic, Wegovy, Mounjaro & Zepbound

Free GLP-1 tracker apps compared with paid ones. Regimen is free for one medication, medication-level chart included. Shotsy, MeAgain, Glapp and 3 more. 14 min read

Retatrutide vs Tirzepatide (Mounjaro): Triple vs Dual Agonist Comparison

Retatrutide vs tirzepatide compared: Phase 3 weight loss data (28.3% vs 22.5%), triple vs dual agonist mechanisms, side effects, cost, and how to switch. Updated with TRIUMPH-1 results. 10 min read

Retatrutide Dosage: The Complete Guide

How much retatrutide should you take per week? Lilly's big trial (TRIUMPH-1) started everyone at 2 mg a week and went up about every four weeks, to as much as 12 mg. In Regimen's app data, 53% of first injections were under 2 mg, and the typical person settled around 4 mg a week. 9 min read

Retatrutide Side Effects: What to Expect, Start to Finish

Every retatrutide side effect in one place: the week-by-week timeline, the glucagon-specific ones, and when to call your provider. 9 min read

How to Reconstitute Retatrutide: Mixing, BAC Water & Dose Math

Reconstitute retatrutide 5mg, 12mg, or 30mg vials with 1 to 3mL BAC water for 5 to 15 mg/mL. Unit math for 2 to 12mg doses on a 100-unit insulin syringe. 8 min read

GLP-1 Plateau: Why You Stopped Losing Weight on Semaglutide or Tirzepatide (and What to Do About It)

How to tell a real GLP-1 plateau from a fake stall, the 7 most common causes, when to increase your dose vs. wait, and tracking strategies to break through weight loss stalls on Ozempic, Wegovy, Mounjaro, or Zepbound. 12 min read

Semaglutide Reconstitution Calculator - How to Mix Compounded Semaglutide

How to reconstitute compounded semaglutide. Free calculator for 5mg and 10mg vials, BAC water amounts, insulin syringe units, and step-by-step instructions. 8 min read

Ozempic Click Chart: What Your Pen Can Actually Do

Ozempic click counts belong to one pen: 18, 36 and 72 clicks are the 1.34 mg/mL pen. Check your carton first, because the same clicks are a different dose. 5 min read

Wegovy Click Chart: Every Dose and What the Clicks Mean

How many clicks are in a Wegovy pen? Two on the single-dose pen, and neither is a dose: click 1 means the injection has started, click 2 that it's still going. On the four-dose FlexTouch the clicks are the dose selector turning, and the dose counter shows your dose. Below: the full dose chart from 0.25 to 7.2 mg. 8 min read

Mounjaro Dose Chart: All Six Doses and How the Pen Works

What are the doses of Mounjaro? There are six weekly strengths: 2.5, 5, 7.5, 10, 12.5 and 15 mg. You start on 2.5 mg for four weeks, then 5 mg; after that, 2.5 mg steps at least four weeks apart, only if needed. Below: the dose chart, how each pen works and the missed-dose rule. 5 min read